Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada.

Tang, P A; Hay, A E; O'Callaghan, C J; Mittmann, N; Chambers, C R; Pater, J L; Leighl, N B

Tang, P A; Hay, A E; O'Callaghan, C J; Mittmann, N; Chambers, C R; Pater, J L; Leighl, N B.

Afiliación

Tang PA; Tom Baker Cancer Centre, University of Calgary, Calgary, AB;
Hay AE; ncic Clinical Trials Group, Kingston, ON;
O'Callaghan CJ; ncic Clinical Trials Group, Kingston, ON;
Mittmann N; ncic Clinical Trials Group, Kingston, ON;; Health Outcomes and Pharmacoeconomic (hope) Research Centre, Sunnybrook Health Sciences Centre, Toronto, ON;
Chambers CR; Tom Baker Cancer Centre, University of Calgary, Calgary, AB;
Pater JL; ncic Clinical Trials Group, Kingston, ON;
Leighl NB; Princess Margaret Cancer Centre, Toronto, ON.

Curr Oncol ; 23(Suppl 1): S7-S13, 2016 Feb.

Article en En | MEDLINE | ID: mdl-26985151

Palabras clave

Cost avoidance; phase iii trials

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline / Health_economic_evaluation / Prognostic_studies Idioma: En Revista: Curr Oncol Año: 2016 Tipo del documento: Article Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google